Skip to content

Model 486-02 Endocardial Pacing Lead

by Intermedics, Inc. 510(k)

Active United States

510(k) K860547

Regulatory status

as of 29 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK860547 Date13 Jun 1986ClearedStatusActive

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Recalls

0 recalls · FDA

No FDA recalls on record, checked 22 Oct 2026.

Specification

510(k)

510(k) Number
FDA Product Code
DTB
Device Class
Class III
Regulation
21 CFR Part 870.3680
Advisory Committee
Cardiovascular
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Model 486-02 Endocardial Pacing Lead is a permanent pacemaker electrode, designed to deliver electrical stimulation to the heart’s endocardial tissue. It facilitates cardiac pacing by transmitting impulses from an external pacemaker to the right atrium or ventricle, helping regulate abnormal heart rhythms in patients requiring chronic pacing support.

This device is intended for transvenous implantation and is supplied sterile for single-use. It is classified as a Class III medical device under FDA regulations (870.3680) and holds a Traditional 510(k) clearance (K860547) for substantial equivalence. Storage and handling must comply with sterile medical device protocols, and its use is governed by FDA-authorized indications for permanent cardiac pacing.

Other devices from Intermedics, Inc.

See all devices from Intermedics, Inc. →

Questions

AI-generated answers, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What is the primary purpose of the Model 486-02 Endocardial Pacing Lead, and how does it function in the body?

    The Model 486-02 Endocardial Pacing Lead is designed to deliver electrical stimulation to the heart’s endocardial tissue, specifically the right atrium or ventricle. It transmits pacing impulses from an external pacemaker device to help regulate abnormal heart rhythms in patients who require chronic cardiac pacing support. This lead is implanted transvenously, meaning it is inserted through a vein and positioned inside the heart to ensure precise electrical conduction.

  • Is the Model 486-02 Endocardial Pacing Lead intended for single-use or reusable applications, and what are the storage requirements?

    The Model 486-02 Endocardial Pacing Lead is supplied sterile and intended for single-use only. Due to its sterile packaging, storage must comply with standard sterile medical device protocols to maintain integrity until use. Improper storage could compromise sterility, so it should be kept in a clean, dry environment away from direct sunlight or extreme temperatures.

  • What regulatory pathway was followed for FDA clearance of this device, and which advisory committee was involved?

    The Model 486-02 Endocardial Pacing Lead received a Traditional 510(k) clearance (K860547) under the FDA’s substantial equivalence determination, meaning it was deemed comparable to a legally marketed predicate device. The review was conducted by the Cardiovascular (CV) Advisory Committee, which evaluates medical devices related to heart function and vascular health.

  • How is this lead classified under FDA regulations, and what does that classification imply for its use?

    The Model 486-02 Endocardial Pacing Lead is classified as a Class III medical device (870.3680) under FDA regulations. This classification is reserved for devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. As a Class III device, it requires pre-market approval (or in this case, a 510(k) clearance) to ensure safety and effectiveness before commercial distribution.